Vascular Biogenics Ltd. Announces $24 Million Registered Direct Offering
June 07, 2016 07:44 ET
|
VBL Therapeutics
TEL AVIV, Israel, June 07, 2016 (GLOBE NEWSWIRE) -- Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ:VBLT), today announced that it has agreed to the sale and issuance of...
VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer
June 06, 2016 07:00 ET
|
VBL Therapeutics
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042)60% (9 of 15) durable response rate (as measured by...
Clinical Data Presented at ASCO Demonstrate Significant Overall Survival Benefit in rGBM Patients Receiving VB-111 Compared with Historical Avastin® Meta-analysis Data
June 03, 2016 16:02 ET
|
VBL Therapeutics
VBL's Phase 2 study in recurrent glioblastoma (rGBM) met the primary endpoint of statistically-significant increase in median overall survival, with 59 weeks in patients treated with continuous...
VBL Therapeutics Announces First Quarter 2016 Financial Results and Provides Business Update
May 13, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 13, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report First Quarter 2016 Financial Results on May 13
May 05, 2016 16:02 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...
VBL Therapeutics Announces Clinical Data to be Presented at 2016 ASCO Annual Meeting
May 03, 2016 11:02 ET
|
VBL Therapeutics
TEL AVIV, Israel, May 03, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Host Key Opinion Leader Meeting on Wednesday, May 4 in New York City
April 27, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, April 27, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Publication of NASH Data for Lecinoxoids Molecules VB-201 and VB-703
April 19, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, April 19, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics Announces Full-Year 2015 Financial Results and Provides Business Update
March 29, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 29, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
VBL Therapeutics to Report Fourth Quarter & Fiscal Year 2015 Financial Results on March 29
March 07, 2016 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, March 07, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of...